NOC2 like nucleolar associated transcriptional repressor pseudogene 1Genealiases: []
Q-omics provides the consensus-scored NOC2LP1 profile across patient tissues and cancer cell-line models. NOC2LP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NOC2LP1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, NOC2LP1 RNA expression shows 10,274 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, THCA, and TGCT as cancer lineages where NOC2LP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOC2LP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOC2LP1 survival associations across molecular data types. NOC2LP1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOC2LP1 RNA expression–survival associations across cancer types. High NOC2LP1 expression shows unfavorable associations in BLCA, OV and LIHC, but favorable associations in BRCA, THCA and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for NOC2LP1 RNA expression.
This table summarizes NOC2LP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NOC2LP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOC2LP1 shows lower tumor expression in THCA, KIRC, KICH, UCEC, BLCA and COAD. The THCA box plot shows higher NOC2LP1 RNA expression in normal versus tumor tissue (log2 FC = −2.151, t-test p < 0.001).
This table shows molecular features associated with NOC2LP1 in patient tissues and cancer cell lines. In patient samples, NOC2LP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
